Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Essex Bio-Technology ( (HK:1061) ) has issued an announcement.
Essex Bio-Technology Limited has announced a proposed final ordinary cash dividend of HKD 0.07 per share for the financial year ended 31 December 2025, subject to shareholder approval on 26 May 2026. The ex-dividend date is set for 28 May 2026, with the record date on 3 June 2026 and payment scheduled for 12 June 2026, signaling management’s confidence in the company’s financial performance and providing a modest income return to shareholders.
The dividend will be paid in Hong Kong dollars with no withholding tax applicable, and Computershare Hong Kong Investor Services Limited will serve as the share registrar handling entitlement and registration matters. This payout structure underscores Essex Bio-Technology’s ongoing commitment to shareholder returns and may enhance the stock’s appeal among income-focused investors in the Hong Kong biotechnology sector.
The most recent analyst rating on (HK:1061) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.
More about Essex Bio-Technology
Essex Bio-Technology Limited is a Hong Kong-listed company, trading under stock code 01061. The firm operates in the biotechnology and pharmaceutical sector, focusing on developing and marketing therapeutic products, with its shares held by a mix of institutional and retail investors on the Hong Kong market.
Average Trading Volume: 476,197
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.08B
See more data about 1061 stock on TipRanks’ Stock Analysis page.